Copyright © 2026 A&T Respiratory Lectures All Rights Reserved
Authored by Terrence Shenfield, MS, RRT-ACCS, RPFT, NPS, AE-C
Asthma therapy has seen radical advancements, but one approach stands out in revolutionizing patient care—biomarkers. With the rise of asthma biomarkers, personalized asthma treatment is no longer a far-fetched concept. It’s a reality that offers improved symptom control, reduced exacerbations, and a more patient-centric approach to care.
This blog will explore what biomarkers are, how they play a role in asthma therapy, and why they are paving the way for personalized asthma treatments.
Asthma biomarkers are measurable biological indicators that provide insights into a patient’s asthma phenotype, severity, and response to treatment. These biomarkers are essentially the map that guides healthcare professionals to tailor asthma therapy based on the specific characteristics and needs of an individual patient.
Common asthma biomarkers include eosinophils, exhaled nitric oxide (FeNO), periostin, and immunoglobulin E (IgE). Each sheds light on underlying inflammatory pathways and patient-specific triggers for asthma exacerbations.
The old “one-size-fits-all” approach to asthma treatment often led to over-prescription of medications or under-management of symptoms. Biomarkers bridge this gap by enabling targeted interventions.
Improved efficacy: Treatments guided by biomarkers often result in better symptom control.
Minimized side effects: Patients receive therapies tailored to their needs, avoiding unnecessary medications.
Early detection of worsening symptoms: Biomarkers can indicate inflammation or exacerbations before symptoms manifest clinically.
For example, measuring FeNO provides insights into airway inflammation, making it an essential tool for monitoring treatment progress.
Asthma phenotypes describe the specific type of asthma a person has, factoring in triggers, inflammation profiles, and genetic markers. Understanding asthma phenotypes allows clinicians to customize treatments.
Eosinophilic Asthma
Biomarker: High eosinophil counts
Treatment options include biologics targeting IL-5 or IL-4 pathways.
Allergic Asthma
Biomarker: Specific IgE levels
Common treatments involve allergen immunotherapy and anti-IgE monoclonal antibodies.
Non-Eosinophilic Asthma
Biomarker: Normal eosinophil count but persistent symptoms
Targeted sputum analysis or therapy adjustments may be more effective.
By identifying the right asthma phenotype, clinicians can make informed decisions on treatment plans, improving patient outcomes significantly.
Ongoing asthma research continues to shed light on new biomarkers and treatments. For instance, advancements in genetics and proteomics have identified novel targets, including TSLP (thymic stromal lymphopoietin) as a significant player in asthma inflammation.
Clinical trials testing biologics aimed at emergent pathways are proving promising for severe asthma cases. Stay up-to-date with cutting-edge discoveries by attending live AARC-Approved respiratory therapy webinars.
Understand the Patient’s Phenotype:
Use diagnostic tools to categorize asthma into phenotypes for more targeted asthma therapy.
Leverage Biomarkers for Decision-Making:
Tests like FeNO, peripheral blood eosinophil count, and IgE levels offer invaluable guidance for treatment selection.
Consider Biologic Therapies for Severe Cases:
Biologics such as dupilumab, mepolizumab, or omalizumab are game-changers when identified biomarkers indicate their use.
Monitor Biomarkers Regularly:
Biomarker readings should be refreshed during follow-up visits to track therapy efficacy and symptom progression.
Educate Patients:
Share progress reports with patients, explaining the importance of biomarkers in their treatment. Effective education fosters adherence.
Want to expand your knowledge of asthma care further? Explore comprehensive online courses by A&T Respiratory Lectures.
Despite its promise, implementing biomarker-driven treatments for asthma comes with challenges:
Cost and Accessibility: Tests for biomarkers like FeNO may be cost-prohibitive in underserved areas.
Standardization Issues: Biomarker cut-off values can vary, leading to inconsistent treatment approaches.
Broad Applications Needed: More research is required to improve the utility of biomarkers in non-severe asthma cases.
By addressing these challenges, the healthcare industry can expand the availability of personalized asthma treatment for all.
Looking ahead, the integration of artificial intelligence and machine learning may further enhance biomarker utility. Predictive analytics could analyze vast datasets from asthma research to uncover entirely new biomarker correlations.
Professionals in the respiratory care field should stay proactive in learning about these advancements. Engaging in live AARC-approved respiratory webinars equips clinicians with up-to-date information and strategies to tackle even the most complex asthma cases.
Asthma biomarkers redefine how we approach treatment by empowering healthcare professionals with data-driven insights tailored for each patient. Whether it’s identifying the right biologic therapy or adjusting treatment plans based on FeNO levels, the role of biomarkers in asthma care is undeniable.
Healthcare providers have an exciting opportunity to harness the wealth of knowledge derived from biomarkers to provide personalized, impactful care for their patients. By narrowing the focus from a broad asthma diagnosis to phenotype-specific therapy, clinicians ensure that every breath matters.
To learn more about respiratory care advancements, explore A&T’s comprehensive online asthma courses. Stay ahead in the field of personalized asthma treatment!
Global Initiative for Asthma (GINA). (2023). Global strategy for asthma management and prevention.
Fahy, J. V. (2022). Biomarkers in severe asthma. Journal of Clinical Investigation.
Jackson, D. J., et al. (2023). Emerging biologic treatments for asthma. The Lancet Respiratory Medicine.
National Asthma Education and Prevention Program (NAEPP). Updates in asthma management. (2023).
Wenzel, S. E. (2022). Asthma phenotypes and endotypes. The AMA Journal of Medicine.
Respiratory care changes fast. At A&T Respiratory Lectures, we want to help you stay ahead.
Our articles are great for everyone. Experienced therapists use them to improve patient care. Newcomers use them to grow their careers. We provide the tools you need to succeed.